(Adnkronos) - L’anticorpo monoclonale tezepelumab, unico farmaco biologico anti-Tslp approvato in grado di agire a livello della barriera epiteliale, ha dimostrato di poter essere un'opzione terapeutica di grande rilevanza per il trattamento della rinosinusite cronica con poliposi nasale. Già approvato e rimborsato in Italia per il trattamento dell’asma grave non controllato, il farmaco si è rivelato efficace, rispetto al placebo, nel ridurre in maniera significativa la severità dei polipi nasali, il bisogno di ricorrere a un intervento chirurgico e di assumere corticosteroidi sistemici per la poliposi nasale. Lo confermano i risultati dello studio di fase 3 Waypoint, presentati in anteprima al Congresso Aaaai - American academy of allergy, asthma and immunology e discussi nel corso di un incontro con la stampa organizzato da AstraZeneca a Milano.
Category
🗞
NewsTranscript
00:00The impact of severe asthma and chronic rhinosinusitis with nasal polyposis on the quality of life
00:09of those who suffer from it can be very important, both from a physical and psychological point
00:14of view.
00:15It involves limitations in daily activities, sleep disorders and sometimes even anxiety
00:18or depression.
00:19According to the data of the Italian Register of Severe Asthma, 42% of subjects affected
00:24by this pathology also suffer from nasal polyposis.
00:27To mediate the immune response of the inflammatory type as a result of the damage of the epithelial barrier
00:32caused by allergens, pollution or virus, there are in both pathologies a particular type
00:37of cytokines, alarmines, among which TSLP plays a fundamental role.
00:42The anti-TSLP, that is, the monoclonal antibody that blocks this alarmine, the Tezepelumab,
00:50is currently available as far as bronchial asthma is concerned, but recently at the American
00:57Academy and World Allergy Organization in San Diego, last week, and at the same time
01:04at the New England Journal of Medicine, the data on the efficacy of Tezepelumab were released
01:12in the clinical trial of rhinosinusitechronica with nasal polyposis, and it was an extremely
01:20interesting fact because the efficacy was demonstrated on all the parameters that have been studied.
01:28This is the study of Phase 3 Waypoint, which demonstrates how Tezepelumab can be a therapeutic
01:34option of great relevance also for the treatment of rhinosinusitechronica with nasal polyposis.
01:39In this study, Tezepelumab has been shown to be effective in reducing the size of the polyps,
01:46in significantly improving olfactory sensitivity, and in reducing other symptoms associated with the
01:55disease. In addition, Tezepelumab, in this particular category of patients who are
02:02severely affected, has been shown to be effective in reducing, for 98% of them,
02:11the need for a new surgical intervention, and for 88% of them to reduce the need for
02:18systemic corticosteroids. Tezepelumab, the only anti-TSLP biological drug approved,
02:24capable of acting at the epithelial barrier level, is the result of the commitment, research and
02:28development of AstraZeneca. AstraZeneca has always been committed to research and development,
02:34especially in the field of respiratory and immunological pathologies, and Tezepelumab
02:41represents a pioneering approach by AstraZeneca in targeting TSLP as an epithelial cytokine
02:52of a inflammatory cascade. This new molecule has already shown to be extremely effective and safe
02:59in the field of severe asthma, and today, thanks to the results of the Waypoint study,
03:04we know that it is just as effective and safe also in subjects affected by chronic rhinosinusitis
03:12and polyposis nasal. This is certainly an important milestone for us that allows us to
03:21progress in our research and development of new therapeutic targets in the field of
03:27precision medicine in respiratory and immunology.